- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
Cytolon successful with second financing round
Cytolon AG has successfully completed its second financing round acquiring a multi-million euro investment in the company.
Berlin, 18 April 2011. Cytolon AG has successfully completed its second financing round, a multi-million euro financing round with institutional and private investors.
“We are very pleased that following the conclusion of our second financing round, we are now able to push forward with the worldwide commercialization of our IT-based matching platform, CordMatch®,” said Thomas Klein, founder and Chief Executive Officer of Cytolon AG. “Furthermore, we intend to build additional applications into CordMatch® that will offer registries, clinics, and cord blood banks further possibilities for the use of the platform,” continued Klein.
About CordMatch®
CordMatch® offers efficient, cost saving solutions which enable transplant centers, donation registries, stem cell banks, and pharmaceutical companies to provide individually matched stem cell preparations for a high number of cases worldwide. Furthermore, CordMatch® is the first to set a standard for the simultaneous transplantation of multiple units of cord blood. This will be a key requirement for the future of stem cell therapies.
About Cytolon
Cytolon AG is a technology oriented service provider positioning itself as the first company worldwide to offer intelligent internet platforms that will become necessary for the field of personalized medicine. Cytolon’s first product is an internet based matching platform, CordMatch®. CordMatch® offers efficient cost saving solutions to transplant centers, donor registries, stem cell banks, and pharmaceutical companies which make it possible to provide individually matched stem cell preparations for a high number of cases worldwide.
Cytolon was founded in 2008 by Thomas Klein. In 2009 Cytolon AG was awarded the “most promising company launched" by Deutsche Bank, Hasso Plattner Ventures. Cytolon is a member of the Association of Research-Based Pharmaceutical Companies (VfA) and the Federal Association for Information Technology, Telecommunications and New Media (BITKOM). Further information can be found at www.cytolon.com.
Press Contact
Hanna Dudenhausen - Public Relations/ Investor Relations
Cytolon AG
Am Karlsbad 15
10785 Berlin
mobile +49 (0) 151 291 091 26
phone: +49 (0) 30 26 39 288 0
fax: +49 (0) 30 26 39 288 20
e-mail: hanna.dudenhausen@cytolon.com